LIFE AI

924 posts

LIFE AI banner
LIFE AI

LIFE AI

@LifeNetwork_AI

The Intelligence Layer of Human Health, @avax Avalanche’s flagship L1 for Healthcare AI. https://t.co/K3oS6fhvZj | https://t.co/DVjbfufogS

Katılım Mart 2024
355 Takip Edilen65K Takipçiler
Sabitlenmiş Tweet
LIFE AI
LIFE AI@LifeNetwork_AI·
𝗡𝗩𝗜𝗗𝗜𝗔 𝗚𝗧𝗖 𝗧𝗮𝗶𝘄𝗮𝗻 𝟮𝟬𝟮𝟲 - 𝗠𝗮𝗽𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 #𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao @tuan_lifeai presented “LifeAI Biohub: A Purpose-built AI platform for Drug Development” One signal emerged throughout the session: As AI capabilities continue to advance, the bottleneck is no longer intelligence itself. It is the infrastructure that enables validation, governance, and coordination across the full spectrum of healthcare stakeholders. 𝗧𝗵𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 Pharma → Hospitals → Doctors → Labs → Regulators → Auditors → Patients Sustainable progress in healthcare AI demands alignment across the entire ecosystem, not isolated optimization within a single organization. 𝗟𝗶𝗳𝗲𝗔𝗜 𝗕𝗶𝗼𝗛𝘂𝗯 Shared Infrastructure → Coordination Layer → Connected Network → Application Success This is the foundation Life AI is building: the shared infrastructure and coordination layer for the healthcare AI value chain so that every application built on top can move faster, scale further, and earn trust across the industry. The long-term opportunity in healthcare AI will not be defined by better models alone. It will be defined by the infrastructure that makes those models deployable, accountable, and impactful at scale. It was a privilege to share this vision alongside the researchers, healthcare leaders, and technology builders at NVIDIA GTC Taiwan shaping the next chapter of AI.
LIFE AI tweet mediaLIFE AI tweet mediaLIFE AI tweet mediaLIFE AI tweet media
English
405
321
704
201.9K
LIFE AI
LIFE AI@LifeNetwork_AI·
Diagnostics. Research. Monitoring. Records. The instruments of medicine have always existed in pieces. The next step isn't creating more tools. It's bringing them together into a connected health infrastructure.
LIFE AI tweet media
English
50
87
194
5.4K
LIFE AI
LIFE AI@LifeNetwork_AI·
A drug spends years in trials, then decades in the real world. The real world generates far more evidence about how it actually performs than any trial. That evidence rarely goes anywhere. Which patients respond. What side effects emerge. How it behaves across populations the trial never tested. The most valuable evidence in the entire lifecycle — and it almost never flows back into what gets discovered or trialed next. Every new program starts from the same incomplete picture as the last. AI can generate more candidates than ever. But a pipeline that can’t learn from its own history won’t produce a different outcome. The missing infrastructure isn’t discovery. It’s the loop back.
LIFE AI tweet media
English
27
118
193
12.2K
LIFE AI
LIFE AI@LifeNetwork_AI·
In the last 30 years, computing power has increased by a factor of a trillion. Yet developing a new therapy remains one of the slowest, most expensive, and most failure-prone processes in modern science. This is the paradox worth understanding. AI has accelerated target identification. Gene sequencing has collapsed from years to days. Computational modeling can simulate molecular interactions at a scale that was unimaginable a decade ago. Yet the pipeline moves at the same pace. The reason is that technology has made individual stages of the process faster. What it has not changed is the structure of the process itself. Drug development is still sequential. Each stage waits for the one before it. Each program still assembles its own evidence infrastructure from scratch. The handoff between controlled validation and real-world performance still happens after approval. Better tools applied to a fragmented, sequential process produce better science at the same speed. What compresses the timeline is not faster tools inside the existing structure. It is a different structure entirely.
LIFE AI tweet media
English
39
137
232
12.4K
LIFE AI
LIFE AI@LifeNetwork_AI·
AI can now generate drug candidates at a scale the industry has never seen. But the number of drugs reaching patients has not changed. The pipeline is fuller than ever. The outcome is the same. Validation still takes years. Trials still require building evidence from scratch. And the real-world signal that determines whether a drug actually works for real patients still arrives too late to change anything. More discovery without better infrastructure doesn’t accelerate medicine. It creates a longer queue.
LIFE AI tweet media
English
23
134
250
14.3K
LIFE AI
LIFE AI@LifeNetwork_AI·
We've spent enough time touching screens this week. Now touch life.
LIFE AI tweet media
English
54
130
251
12.1K
LIFE AI
LIFE AI@LifeNetwork_AI·
Clinical trials are the most expensive phase of drug development. They are also the phase most likely to fail. Phase I: testing safety in a small group. Phase II: testing efficacy in a larger group. Phase III: confirming results across a broad population. Each phase takes years. Each phase requires recruiting participants who fit narrow eligibility criteria. And each phase validates a drug against a controlled population that rarely reflects the biological diversity of the patients it will eventually serve. This is the fundamental problem with how clinical trials are designed. The evidence is generated in a controlled environment. The drug is deployed in the real world. The gap between those two contexts is where most post-market failures begin. Real-world validation — continuous, population-diverse, outside the trial — is not a supplement to clinical trials. It is what makes the evidence from clinical trials actually predictive.
LIFE AI tweet media
English
29
127
212
13.3K
LIFE AI
LIFE AI@LifeNetwork_AI·
A celebration of passion, connection, and the human spirit. Welcome to World Cup 2026. 🌍⚽
LIFE AI tweet media
English
31
121
229
12.5K
LIFE AI
LIFE AI@LifeNetwork_AI·
Bringing a single drug to market takes 12 to 15 years and costs up to $2.6 billion. Despite that investment, 90% of drug candidates that enter clinical trials never reach approval. The reason is not that the science is wrong. It is that the process was never designed to learn continuously. The drug development lifecycle has 7 stages: 1. Target Discovery 2. Drug Discovery 3. Lead Optimization & Candidate Selection 4. Preclinical Research 5. Clinical Trials 6. Regulatory Review 7. Post-Market Monitoring & Patient Access Every stage runs sequentially. Every handoff introduces delay. Every program builds its own evidence infrastructure from scratch. And the real-world signal generated in stage 7 - how a drug actually performs in real patients never flows back to inform the decisions made in stages 1 through 3. That missing feedback loop is where most of the time, cost, and failure lives.
LIFE AI tweet media
English
36
134
249
9.1K
LIFE AI
LIFE AI@LifeNetwork_AI·
Everything in life comes back to health.
English
36
125
255
10.6K
LIFE AI
LIFE AI@LifeNetwork_AI·
Weekend prescription from Life AI 💚 ✓ Get some sunlight ☀️ ✓ Take a walk 🚶 ✓ Touch grass 🌱 Sometimes the most powerful health upgrade is completely free.
LIFE AI tweet media
English
50
140
304
10.4K
LIFE AI retweetledi
Tuan Cao
Tuan Cao@tuan_lifeai·
** NVIDIA GTC Taipei: Memorable experience ** I've passed through Taiwan in transit plenty of times, but this was my first time actually staying here. Taipei is a beautiful city. On the ride from the airport, my Uber driver asked if I was here for the NVIDIA conference. He'd doubled his shifts, he said, because so many people were flying in for NVIDIA's GTC, which runs alongside Computex this year. The whole city was buzzing. We're proud that Life AI was one of 15 startups picked to present on Startup Day. Robotics and Physical AI are everywhere right now. So is AI for Life Sciences. I had so many good conversations after our session. The question I kept getting was a simple one: why exactly is drug development so slow and expensive? Over the past year, more and more AI-led drug discovery companies, each raised hundreds of millions of dollars. It feels like the whole AI world is obsessed with drug discovery right now. And yes, drug development really is slow and expensive. Creating a promising drug candidate is hard. Proving it actually works in people is an order of magnitude harder. AI has largely cracked the first half, producing drug candidates at a fraction of the old cost. The second half, the clinical work that proves a drug actually works, is still painfully slow and expensive. That gap is exactly where we come in. AI now produces far more candidates than the industry can possibly develop, which leaves a growing pile of shelved, clinically-informed assets that nobody is taking forward. That's Life AI's wedge: asset rescue. We in-license these drug assets, finish the development in Asia at a fraction of the US cost, and share the upside. @IsomorphicLabs , the Google DeepMind spin-off, just closed a $2.1B round and is arguably leading the world in AI drug discovery. One day I'd love to sit down with their team and say: thank you, thank you for producing so many promising candidates. Life AI is here to rescue them.
LIFE AI@LifeNetwork_AI

𝗡𝗩𝗜𝗗𝗜𝗔 𝗚𝗧𝗖 𝗧𝗮𝗶𝘄𝗮𝗻 𝟮𝟬𝟮𝟲 - 𝗠𝗮𝗽𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 #𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao @tuan_lifeai presented “LifeAI Biohub: A Purpose-built AI platform for Drug Development” One signal emerged throughout the session: As AI capabilities continue to advance, the bottleneck is no longer intelligence itself. It is the infrastructure that enables validation, governance, and coordination across the full spectrum of healthcare stakeholders. 𝗧𝗵𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 Pharma → Hospitals → Doctors → Labs → Regulators → Auditors → Patients Sustainable progress in healthcare AI demands alignment across the entire ecosystem, not isolated optimization within a single organization. 𝗟𝗶𝗳𝗲𝗔𝗜 𝗕𝗶𝗼𝗛𝘂𝗯 Shared Infrastructure → Coordination Layer → Connected Network → Application Success This is the foundation Life AI is building: the shared infrastructure and coordination layer for the healthcare AI value chain so that every application built on top can move faster, scale further, and earn trust across the industry. The long-term opportunity in healthcare AI will not be defined by better models alone. It will be defined by the infrastructure that makes those models deployable, accountable, and impactful at scale. It was a privilege to share this vision alongside the researchers, healthcare leaders, and technology builders at NVIDIA GTC Taiwan shaping the next chapter of AI.

English
14
46
127
2.5K
LIFE AI
LIFE AI@LifeNetwork_AI·
If the problem is coordination across an entire healthcare value chain, the infrastructure has to be built for that from the ground up. That is what Life AI is. The shared infrastructure and coordination layer that connects pharma, hospitals, doctors, labs, regulators, auditors, and patients, with their interests aligned around each application's success. At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao took the stage to present exactly how Life AI is building that infrastructure and why it matters for the future of healthcare.
LIFE AI tweet media
LIFE AI@LifeNetwork_AI

𝗡𝗩𝗜𝗗𝗜𝗔 𝗚𝗧𝗖 𝗧𝗮𝗶𝘄𝗮𝗻 𝟮𝟬𝟮𝟲 - 𝗠𝗮𝗽𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 #𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao @tuan_lifeai presented “LifeAI Biohub: A Purpose-built AI platform for Drug Development” One signal emerged throughout the session: As AI capabilities continue to advance, the bottleneck is no longer intelligence itself. It is the infrastructure that enables validation, governance, and coordination across the full spectrum of healthcare stakeholders. 𝗧𝗵𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 Pharma → Hospitals → Doctors → Labs → Regulators → Auditors → Patients Sustainable progress in healthcare AI demands alignment across the entire ecosystem, not isolated optimization within a single organization. 𝗟𝗶𝗳𝗲𝗔𝗜 𝗕𝗶𝗼𝗛𝘂𝗯 Shared Infrastructure → Coordination Layer → Connected Network → Application Success This is the foundation Life AI is building: the shared infrastructure and coordination layer for the healthcare AI value chain so that every application built on top can move faster, scale further, and earn trust across the industry. The long-term opportunity in healthcare AI will not be defined by better models alone. It will be defined by the infrastructure that makes those models deployable, accountable, and impactful at scale. It was a privilege to share this vision alongside the researchers, healthcare leaders, and technology builders at NVIDIA GTC Taiwan shaping the next chapter of AI.

English
58
132
278
11.6K
LIFE AI
LIFE AI@LifeNetwork_AI·
Building a better AI model will not fix healthcare. The real challenge is coordinating an entire value chain: pharma, hospitals, doctors, labs, regulators, auditors, and patients. Each with its own incentives, priorities, compliance obligations, and trust requirements. No single model can coordinate all of that. No single organization can either. Better healthcare comes from better infrastructure for the value chain. That is the problem Life AI was built to solve. #NVIDIAGTC #LifeAI #BioHub #HealthcareAI
LIFE AI tweet media
LIFE AI@LifeNetwork_AI

𝗡𝗩𝗜𝗗𝗜𝗔 𝗚𝗧𝗖 𝗧𝗮𝗶𝘄𝗮𝗻 𝟮𝟬𝟮𝟲 - 𝗠𝗮𝗽𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 #𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao @tuan_lifeai presented “LifeAI Biohub: A Purpose-built AI platform for Drug Development” One signal emerged throughout the session: As AI capabilities continue to advance, the bottleneck is no longer intelligence itself. It is the infrastructure that enables validation, governance, and coordination across the full spectrum of healthcare stakeholders. 𝗧𝗵𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 Pharma → Hospitals → Doctors → Labs → Regulators → Auditors → Patients Sustainable progress in healthcare AI demands alignment across the entire ecosystem, not isolated optimization within a single organization. 𝗟𝗶𝗳𝗲𝗔𝗜 𝗕𝗶𝗼𝗛𝘂𝗯 Shared Infrastructure → Coordination Layer → Connected Network → Application Success This is the foundation Life AI is building: the shared infrastructure and coordination layer for the healthcare AI value chain so that every application built on top can move faster, scale further, and earn trust across the industry. The long-term opportunity in healthcare AI will not be defined by better models alone. It will be defined by the infrastructure that makes those models deployable, accountable, and impactful at scale. It was a privilege to share this vision alongside the researchers, healthcare leaders, and technology builders at NVIDIA GTC Taiwan shaping the next chapter of AI.

English
24
124
215
8.7K
LIFE AI
LIFE AI@LifeNetwork_AI·
Healthcare has AI in every vertical. AI doctors. AI diagnostics. AI copilots. AI imaging. AI drug discovery. AI trial matching. AI revenue cycle. Yet healthcare still looks mostly the same. Cancer is not yet cured. Drug prices are not yet lowered. Care is not yet personalized. AI is transforming every industry. Why not yet healthcare? That is the question Dr. Tuan Cao, Co-Founder & CEO of Life AI, posed at NVIDIA GTC Taiwan 2026 and the problem Life AI is building to solve.
LIFE AI tweet media
LIFE AI@LifeNetwork_AI

𝗡𝗩𝗜𝗗𝗜𝗔 𝗚𝗧𝗖 𝗧𝗮𝗶𝘄𝗮𝗻 𝟮𝟬𝟮𝟲 - 𝗠𝗮𝗽𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 #𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 At NVIDIA GTC Taiwan 2026, our Co-Founder & CEO Dr. Tuan Cao @tuan_lifeai presented “LifeAI Biohub: A Purpose-built AI platform for Drug Development” One signal emerged throughout the session: As AI capabilities continue to advance, the bottleneck is no longer intelligence itself. It is the infrastructure that enables validation, governance, and coordination across the full spectrum of healthcare stakeholders. 𝗧𝗵𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻 Pharma → Hospitals → Doctors → Labs → Regulators → Auditors → Patients Sustainable progress in healthcare AI demands alignment across the entire ecosystem, not isolated optimization within a single organization. 𝗟𝗶𝗳𝗲𝗔𝗜 𝗕𝗶𝗼𝗛𝘂𝗯 Shared Infrastructure → Coordination Layer → Connected Network → Application Success This is the foundation Life AI is building: the shared infrastructure and coordination layer for the healthcare AI value chain so that every application built on top can move faster, scale further, and earn trust across the industry. The long-term opportunity in healthcare AI will not be defined by better models alone. It will be defined by the infrastructure that makes those models deployable, accountable, and impactful at scale. It was a privilege to share this vision alongside the researchers, healthcare leaders, and technology builders at NVIDIA GTC Taiwan shaping the next chapter of AI.

English
44
136
248
9.4K
LIFE AI retweetledi
Tuan Cao
Tuan Cao@tuan_lifeai·
** When you think of AI, think of humanity too. ** At the GStar AI & Humanity Summit, I was asked during our panel: what can AI do for humanity? It reminded me of a dinner I had with Thang Luong @lmthang, Director of Research at Google DeepMind. We were deep in the technical side, World Models for healthcare, AI in drug discovery, and we kept coming back to one simple fact: humans are still used as test subjects in drug development. As AI makes drug discovery faster and cheaper, more and more candidates will go into clinical trials. And those trials run on people. About 90% of drug candidates that reach clinical trials fail, so most of the time people take on real risk, including serious side effects, for a candidate that never makes it. So, what can AI do for humanity? Here's one thing I'd love to see: more AI companies building simulation environments that test drug candidates before they ever reach a real trial. Ideally, anything that passes the simulation would have a 99% chance of passing the actual one. It's a hard problem. Of course it is. But it's not so different from how engineers built flight simulators for pilots, which have probably saved thousands of lives. Fingers crossed that experts at Anthropic, OpenAI, and especially Google DeepMind solve this soon. I'd love to help. Tagging Jeff Dean @JeffDean , Quoc Le @quocleix , Thang Luong @lmthang , Ed Chi @edchi , Yi Tay @YiTayML .
LIFE AI@LifeNetwork_AI

A great day at GStar Summit 2026: AI + Humanity. Our Co-Founder & CEO, Dr. Tuan Cao, joined the AI for Healthcare & Life Sciences session to discuss how AI can be applied responsibly in healthcare, where innovation must be matched with trust, safety, and real-world impact. A sincere thank you to the organizers, New Turing Institute and Pacific Gateway Partners, and to Google and FPT Corporation as strategic partners, for bringing together leaders, researchers, and innovators working at the intersection of AI and humanity. We’re grateful for the conversations, connections, and shared commitment to building AI that serves people and improves lives. @tuan_lifeai @newturing @lmthang

English
6
57
109
3.1K
LIFE AI
LIFE AI@LifeNetwork_AI·
A great day at GStar Summit 2026: AI + Humanity. Our Co-Founder & CEO, Dr. Tuan Cao, joined the AI for Healthcare & Life Sciences session to discuss how AI can be applied responsibly in healthcare, where innovation must be matched with trust, safety, and real-world impact. A sincere thank you to the organizers, New Turing Institute and Pacific Gateway Partners, and to Google and FPT Corporation as strategic partners, for bringing together leaders, researchers, and innovators working at the intersection of AI and humanity. We’re grateful for the conversations, connections, and shared commitment to building AI that serves people and improves lives. @tuan_lifeai @newturing @lmthang
LIFE AI tweet mediaLIFE AI tweet mediaLIFE AI tweet mediaLIFE AI tweet media
English
40
129
224
11.5K
LIFE AI
LIFE AI@LifeNetwork_AI·
Welcome to a new month of better health, better habits, and a better life. One step at a time. 💚
LIFE AI tweet media
English
43
131
262
11.2K
LIFE AI
LIFE AI@LifeNetwork_AI·
GLife Catch it if you can 👇
English
54
134
301
15K
LIFE AI
LIFE AI@LifeNetwork_AI·
AI learns. Humans decide. We didn’t build Life AI to replace clinicians. We built it to change what is possible for human health — infrastructure that coordinates across biology, institutions, and real human life. The AI is the coordination layer. The human is the reason it exists.
LIFE AI tweet media
English
40
119
226
11.6K